The effects of high- and medium-dose metfformin therapy on cardiovascular risk factors in patients with type II diabetes

Diabetes Care

Volumn 19, Issue 1, 1996, Pages 64-66

  Grant, Peter J ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; FIBRINOLYSIS; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; TRIACYLGLYCEROL BLOOD LEVEL;

ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PLACEBOS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 0030022720     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.1.64     Document Type: Article

References (11)

1. Grant PJ: The effects of metformin on cardiovascular risk factors. Diabetes Metab Rev 11.543-550, 1995
2. Walmsley D, Hampton KK, Grant PJ: Contrasting fibrinolytic responses in type 1 (insulin dependent) and type 2 (non insulin dependent) diabetes. Diabetic Med 8.954-959, 1991
3. Hamsten A, deFaire U, Waldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii:3-9, 1987
4. Bailey CJ: Biguanides and NIDDM. Diabetes Care 15:755-772, 1992
5. Hermann LS, Schersten B, Melander A: Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabetic Med 11:953-960, 1994
6. McIntyre HD, Ma A, Bird DM, Paterson CA, Ravenscroft PJ, Cameron DP: Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus Aust NZ J Med 21:714-719, 1991
7. Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IRF: One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete & Metab 20:146-149, 1994
8. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16:621-629, 1993
9. United Kingdom Prospective Diabetes Study Group: United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-imsulin dependent diabetes followed for three years. Br Med J 310:83-88, 1995
10. Grant PJ, Stickland MH, Booth NA, Prentice CRM: Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor in type 2 diabetic patients. Diabetic Med 8:361-365, 1991
11. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J: Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic subjects. Thromb Haemostasis 57.326-328, 1987